Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
A case series of GPRC5D bispecific antibody talquetamab-induced dizziness-ataxia syndrome (all patients got 0.8 q2 weeks), including clinical presentation and management suggestions with dexamethasone or cyclophosphamide.”
Title: GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
Authors: Murali Janakiram, Lawrence Liu, Scott Goldsmith, Azra Borogovac, Sarah Lee, Nitya Nathwani, Michael Rosenzweig, Firoozeh Sahebi, Myo Htut
You can read the Full Article on Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
